Author Correction: Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection

Affiliations

• ¹ Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
• ² Immunisation and Countermeasures Division, National Infection Service, London, UK.
• ³ Immunoassay Laboratory, National Infection Service, Porton Down, UK.
• ⁴ Sero-epidemiology Unit, Public Health England, Public Health Laboratory Manchester, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, UK.
• ⁵ Department of Virology, Manchester Medical Microbiology Partnership, Manchester Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, UK.
• ⁶ The NIHR Manchester Clinical Research Facility, Manchester University NHS Foundation Trust, Manchester, UK.
• ⁷ Kellgren Centre for Rheumatology, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, UK.
• ⁸ Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK.
• ⁹ Immunisation and Countermeasures Division, National Infection Service, London, UK. Shamez.Ladhani@phe.gov.uk.
• ¹⁰ Paediatric Infectious Diseases Research Group (PIDRG), St. Georges University of London (SGUL), London, UK. Shamez.Ladhani@phe.gov.uk.
• ¹¹ Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK. P.Moss@bham.ac.uk.